US Pharma MarketingA syphilis drug shortage, Sanofi's diabetes drug approval, and more biotech news from The Readout CMS FDA diabetes Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Newsletter The Readout Lilly’s Ajax acquisition may have been worth it A syphilis drug shortage, Sanofi’s diabetes drug approval, and more…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
A worsening shortage of Bicillin, Pfizer’s injectable form of penicillin, left an Arizona woman unable to receive timely treatment for syphilis during pregnancy.
Also, the FDA approved Sanofi’s diabetes drug Tzield after an unusually contentious review process, and the Trump administration has proposed closing a Medicare negotiation loophole.
Source: STAT News Pharma